![]() ![]() Its occurrence and development begin with the expression of tissue factor and interact with physiological anticoagulation pathways. DIC is a syndrome characterized by the activation of systemic intravascular coagulation, which leads to extensive fibrin deposition in the blood. The characteristic pathological changes of DAD include alveolar epithelial and vascular endothelial injury, increased alveolar membrane permeability, large numbers of neutrophil infiltration, alveolar hyaline membrane formation, and hypoxemia and respiratory distress as the main clinical manifestations. Microvascular thrombosis may lead to microcirculation disorders and multiple organ failure lead to death. Microthrombosis is a prominent clinical feature of COVID-19, and 91.3% of dead patients had microthrombosis.Įndothelial damage caused by SARS-CoV-2 cell invasion and subsequent host response disorders involving inflammation and coagulation pathways play a key role in the progression of severe COVID-19. We summarized the data reported in the past few months and emphasized that the main causes of death of COVID-19 patients are DAD (Diffuse Alveolar Damage) and DIC (Disseminated intravascular coagulation). 3–24.The spread of the coronavirus (SARS-CoV-2, COVID-19 for short) has caused a large number of deaths around the world. Kissling), Steinkopff, Darmstadt, 1983, pp. In: Cardiac Adaptation to Hemodynamic Overload, Training and Stress (Eds. Alpert), Raven Press, New York, 1983, pp. and Thiedemann, K.-U, In: Myocardial Hypertrophy and Failure (Ed. Holubarsch, Ch., Holubarsch, T., Jacob, R., Medugorac, I. Thiedemann, K.-U., Holubarsch, Ch., Medugorac, I. Reindell), Springer, Berlin-Heidelberg-New York, 1982, pp. Pathophysiologic, Diagnostik, Therapie (Eds. Hyperfunktion, Hypertrophie und Insuffizienz des Herzens, VEB Verlag Volk und Gesundheit, Berlin, 1969. Takeda, N., Dominiak, P., Türck, D., Rupp, H. Holubarsch, Ch., Goulette, R.P., Mulieri, LA and Alpert, N.R. Rupp), Thieme, Stuttgart-New York, 1986, pp. Pool, P.E., Covell, J.W., Levitt, M., Gibb, J. In: Myocardial Hypertrophy and Failure (Ed. Jacob, R., Ebrecht, G., Holubarsch, Ch., Rupp H. Jacob, R., Kissling, G., Ebrecht, G., Jörg, E., Rupp, H. Strauer), Springer, Berlin-Heidelberg-New York, 1981, pp. Symposium ‘Inflammatory Heart Disease’, Würzburg, 1986, in press.Įbrecht, G., Rupp, H. Jacob, R., Ebrecht, G., Kissling, F., Rupp, FT and Takeda, N. Mittmann, U., Bruckner, U.B., Keller, H.E., Kohler, U., Vetter, H. Springer, Berlin-Heidelberg-New York, 1980. Jacob, R., Kissling, G., Ebrecht, G., Holubarsch, Ch., Medugorac, I. Section), Meeting Winnipeg, 1986.īurger, S.B. International Society for Heart Research (Amer. ![]() Jeschke), Springer, Berlin-Heidelberg-New York, 1984, pp. In: Stellenwert der Sportmedizin in Medizin und Sportwissenschaft (Ed. ![]() Jacob, R., Kissling, G., Ebrecht, G., Holubarsch, C. Wikman-Coffelt, J., Parmley, W.W., Mason, D.T. Tarazi, R.C., Zanchetti, A.), Elsevier Science Publishers, Amsterdam, 1986, pp. ![]()
0 Comments
Leave a Reply. |